Clinical Trials Logo

Medullary Thyroid Cancer clinical trials

View clinical trials related to Medullary Thyroid Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04280081 Active, not recruiting - Solid Tumor Clinical Trials

A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

LIBRETTO-321
Start date: March 16, 2020
Phase: Phase 2
Study type: Interventional

The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

NCT ID: NCT04211337 Active, not recruiting - Clinical trials for Medullary Thyroid Cancer

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

LIBRETTO-531
Start date: February 11, 2020
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.

NCT ID: NCT03643055 Active, not recruiting - Clinical trials for Medullary Thyroid Cancer

18F-Fluorocholine PET/CT in Medullary Thyroid Cancer

Start date: September 3, 2014
Phase:
Study type: Observational

To assess the diagnostic accuracy of 18F-Fluorocholine PET/CT for the detection of medullary thyroid cancer in patients with primary and recurrent disease.

NCT ID: NCT01896479 Active, not recruiting - Clinical trials for Medullary Thyroid Cancer

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

EXAMINER
Start date: December 2014
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

NCT ID: NCT01298323 Active, not recruiting - Clinical trials for Medullary Thyroid Cancer

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

88
Start date: February 25, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib